Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Low-Grade Glioma Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced May 21, 2026, 7:23 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions
filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lomustine, procarbazine hydrochloride, vincristine sulfate, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
17
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
Interventions
Everolimus
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced May 21, 2026, 7:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Osteosarcoma, Hepatic Tumors, Hepatoblastoma, Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Rhabdomyosarcoma
Interventions
Cobolimab, Dostarlimab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
0 Years to 21 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Iowa City, Iowa • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Temozolomide, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Newark, Delaware + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced May 21, 2026, 7:23 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood, MAP Kinase Family Gene Mutation, NF1, Plexiform Neurofibroma, Low-grade Glioma, Optic Pathway Gliomas, Neuroblastoma, Primary Brain Tumor, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, Central Nervous System Tumor
Interventions
Avutometinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced May 21, 2026, 7:23 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Frameshift Array blood sample test
Genetic
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Day to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced May 21, 2026, 7:23 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain Tumors, Spinal Cord Tumors
Interventions
Temozolomide, Lapatinib
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
6
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced May 21, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Brain Cancer
Interventions
Fluorescein, Fluorescein + ALA
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Low-grade Glioma
Interventions
DAY101
Drug
Lead sponsor
Karen D. Wright, MD
Other
Eligibility
1 Year to 25 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 21, 2026, 7:23 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Low-grade Glioma
Interventions
ReMind iPad app, Healthy SMS texting, In-person cognitive rehabilitation, Telehealth cognitive rehabilitation
Device · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Glioma
Interventions
AG-120, AG881
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Glioma, Astrocytoma, Oligodendroglioma
Interventions
Temozolomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2009 · Synced May 21, 2026, 7:23 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Low Grade Glioma of Brain
Interventions
MRI Scan
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 21, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
Interventions
Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Radiation · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
34
States / cities
Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 21, 2026, 7:23 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
271
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
cilengitide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced May 21, 2026, 7:23 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Brain Cancer, Brain Tumor, Brain Neoplasms, Primary Brain Tumor, Low-grade Glioma, Oligodendroglioma, Meningioma, Low Grade Astrocytoma, Cognitive Dysfunction, Memory Impairment, Memory Disorders, Memory Dysfunction
Interventions
HOBSCOTCH-CA
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma
Interventions
HLA-A2 restricted glioma antigen peptides vaccine, Poly-ICLC
Biological
Lead sponsor
James Felker
Other
Eligibility
12 Months to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced May 21, 2026, 7:23 PM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Glioma
Interventions
NovoTTF-200A, Temozolomide
Device · Drug
Lead sponsor
Santosh Kesari
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Santa Monica, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced May 21, 2026, 7:23 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
PARP Inhibitor BGB-290, Temozolomide (TMZ)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 39 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 7:23 PM EDT